| Website | am-pharma.com |
| Category | BioTech |
| Phone | + 31 (0)30 228 92 22 |
| Employees |
| TOTAL | $42.7M |
| VENTURE FUNDING TOTAL | $42.7M |
| Series D, 9/11 Ysios Capital Kurma Life Science Partners BB Biotech Ventures IDInvest Partners | €29.2M |
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
